Form 8-K - Current report:
SEC Accession No. 0001493152-25-008387
Filing Date
2025-02-26
Accepted
2025-02-26 17:07:29
Documents
16
Period of Report
2025-02-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 52773
2 ex4-1.htm EX-4.1 135270
3 ex4-2.htm EX-4.2 137535
4 ex10-1.htm EX-10.1 65472
  Complete submission text file 0001493152-25-008387.txt   632068

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE gtbp-20250225.xsd EX-101.SCH 3024
6 XBRL LABEL FILE gtbp-20250225_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE gtbp-20250225_pre.xml EX-101.PRE 22365
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3066
Mailing Address 315 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA 94104
Business Address 315 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA 94104 (800) 304-9888
GT Biopharma, Inc. (Filer) CIK: 0000109657 (see all company filings)

EIN.: 941620407 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40023 | Film No.: 25671246
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)